NCT02269163: A reported trial by ProMetic BioTherapeutics, Inc
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02269163 |
|---|---|
| Title | A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics IGIV (Human) 10% in Adults and Children With Primary Immunodeficiency Diseases |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Jan. 26, 2016 |
| Completion date | Jan. 11, 2019 |
| Required reporting date | Jan. 11, 2022, midnight |
| Actual reporting date | July 27, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |